About
Technology
Issues
FAQ
Links
Official Page
Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.